13th-15th October, 2008, Amsterdam
Patient recruitment and retention in clinical trials is the leading bottleneck in the new drug development pipeline. As the recruiting culture becomes more sophisticated and the forces affecting patient enrolment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrolment in clinical trials.

Achieving success in this environment requires trial sponsors to play a larger role in the recruitment process and to develop more collaborative working relationships with all stakeholders, including investigators and patients.

Key Speakers:

  • Astellas, UK, Vice President, Medical Affairs and Health Economics
  • AstraZeneca, Sweden, MD, PhD, Associate Professor
  • Baxter, Austria, Medical Director, Europe
  • Bristol-Myers Squibb, Russia, Clinical Operations Manager
  • Eli Lilly, USA, Director, Global Enrolment Optimization
  • Johnson & Johnson, USA, Director, Global Clinical Operations
  • GlaxoSmithKline, France, Executive Director, Medical Affairs and Clinical Development
  • Novo Nordisk, Denmark, Vice President, Clinical Operations, Trial Management
  • Lundbeck, Belgium, Director, International ClinicalResearch - Paediatric Neuro-Psychiatry
  • Pfizer, India, Head, Clinical Research
  • Roche, Turkey, Head of Clinical Trials
  • Sanofi-Aventis, Portugal, Clinical Trials Director
  • University Hospital Gasthuisberg Leuven, Belgium, Department of Paediatrics

Key topics:

  • The ½ Day pre-conference workshop will focus on retention strategies. Patient non-compliance can run as high as 80% and up to 40% of patients are lost to follow up in a clinical trial costing time and money.
  • Bringing Patient Recruitment into the 21st Century is looking into developing a foward thinking approach, considering public perception with respect to clinical trials, and looking into web-based recruitment
  • Key Components of a Clinical Trial focuses on issues such as communication between pharma, investigator and patient, protocol design and in-house training
  • Analysing Patient Populations addresses feasibility assessments, orphan indications and looks in to paediatric clinical trial challenges. This is followed by Recruiting and Retaining Patients in Emerging Markets where challenges and opportunities in regions such as the CIS, Turkey and India are examined.

Who should attend:
Vice Presidents and Directors of: Patient Recruitment, Patient Retention, Clinical Development, Clinical Operations, Clinical Trials, Clinical Marketing, Clinical Strategy, Clinical Project Management, Medical Affairs, Regulatory Affairs

For further information and registration, please visit:

About Jacob Fleming Group
Jacob Fleming Group is one of the world's leading business intelligence companies producing business-to-business conferences which consists of current research, market trends, technological developments and applications. Our market-led intelligence allows our customers to make informed decisions for maximum bottom-line impact.

Jacob Fleming offices in Bratislava (Slovakia), Prague (Czech republic), Budapest (Hungary), Barcelona (Spain), Dubai (UAE) and Cleveland (USA) specialize in organizing prestigious international conferences for Europe and GCC region, providing groundbreaking strategies and proven technical expertise in both business functional areas and vertical markets through energy, finance, media, pharmaceutical and telecom sectors. For more information, visit www.jacobfleming.com.